Physician profile
Noah Merin
NPI 1659547487
$134,270.01
in general payments reported to CMS, 2019-2025
36 companies · $6,755 in 2025
The $6,755 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $7,649 · 2021: $16K · 2022: $11K · 2023: $24K · 2024: $40K · 2025: $6,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $52K · Food and Beverage: $6,302 · Travel and Lodging: $6,193 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,870 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $51,855.75 |
| Food and Beverage | $6,301.98 |
| Travel and Lodging | $6,192.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,870.00 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $14,216.42 | 2021-2024 | |
| Roche Tcrc, INC. | $13,659.81 | 2019 | |
| Servier Pharmaceuticals LLC | $12,585.10 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10,435.99 | 2019-2024 | Iclusig |
| Genentech USA, INC. | $9,294.33 | 2021-2022 | |
| Incyte Corporation | $9,258.81 | 2024-2025 | Monjuvi |
| Acceleron Pharma, INC. | $8,902.73 | 2021 | |
| Amgen INC. | $8,844.88 | 2019-2025 | Blincyto |
| Kite Pharma, INC. | $7,994.19 | 2021-2023 | Tecartus |
| Gilead Sciences, INC. | $7,190.17 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $6,020.00 | 2023-2024 | Tazverik |
| Agios Pharmaceuticals, INC. | $4,114.90 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,912.05 | 2020-2024 | Calquence |
| Adaptive Biotechnologies Corporation | $2,976.39 | 2022-2023 | Clonoseq |
| Janssen Biotech, INC. | $2,536.59 | 2019-2025 | Darzalex, Carvykti, Rybrevant |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $2,170.00 | 2025 | Elzonris |
| Beigene USA, INC. | $1,970.43 | 2022-2024 | Brukinsa |
| Dova Pharmaceuticals | $1,717.74 | 2020 | |
| Epizyme, INC. | $1,350.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,125.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $761.06 | 2021-2025 | Ultomiris, Soliris |
| Jazz Pharmaceuticals INC. | $477.17 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $476.45 | 2019-2025 | |
| Seagen INC. | $452.26 | 2020-2022 | |
| Celgene Corporation | $344.72 | 2019-2020 | |
| Astellas Pharma US INC | $243.51 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $242.80 | 2022-2025 | Breyanzi |
| Karyopharm Therapeutics INC. | $235.27 | 2021-2024 | Xpovio |
| Genzyme Corporation | $153.61 | 2024 | |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Pfizer INC. | $121.81 | 2025 | |
| Tg Therapeutics, INC. | $120.30 | 2021 | |
| Rigel Pharmaceuticals, INC. | $106.73 | 2024 | Rezlidhia, Tavalisse |
| Abbvie INC. | $100.60 | 2023 | |
| Verastem, INC. | $33.19 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Merin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.